Evidence map›Paper›PMID 25632034›Full record

ArticleScience translational medicine2015

Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients.

Heather Morris, Susan DeWolf, Harlan Robins, Ben Sprangers, Samuel A LoCascio, Brittany A Shonts, Tatsuo Kawai, Waichi Wong, Suxiao Yang, Julien Zuber and 2 more

Open access · greenAbstract read
In one paragraph

Article in Science translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 1 pooled it
20.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 1 synthesis or guideline pooled it, 226 citations in OpenAlex.

  1. Pooled it
  2. Selective decrease of donor-reactive TScience translational medicine · 2022
    Trial
  3. Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Preclinical and clinical studies on kidney allograft tolerance via hematopoietic chimerism.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Tolerance Induction Strategies in Organ Transplantation: Current Status and Future Perspectives.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Review
  19. Article
  20. Chimerism-Mediated Tolerance in Intestinal Transplantation.Gastroenterology clinics of North America · 2024
    Review

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Heather MorrisColumbia University Medical Center, New York, NY 10032, USA.
Susan DeWolfColumbia University Medical Center, New York, NY 10032, USA.
Harlan RobinsFred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Ben SprangersColumbia University Medical Center, New York, NY 10032, USA.
Samuel A LoCascioColumbia University Medical Center, New York, NY 10032, USA.
Brittany A ShontsColumbia University Medical Center, New York, NY 10032, USA.
Tatsuo KawaiMassachusetts General Hospital, Boston, MA 02114, USA.
Waichi WongColumbia University Medical Center, New York, NY 10032, USA.
Suxiao YangColumbia University Medical Center, New York, NY 10032, USA.
Julien ZuberColumbia University Medical Center, New York, NY 10032, USA.
Yufeng ShenColumbia University Medical Center, New York, NY 10032, USA. megan.sykes@columbia.edu ys2411@columbia.edu.
Megan SykesColumbia University Medical Center, New York, NY 10032, USA. megan.sykes@columbia.edu ys2411@columbia.edu.
Columbia University Irving Medical Center · USFred Hutch Cancer Center · USMassachusetts General Hospital · US

Funding

Transcriptomics and Repertoire ProfilingP01AI106697 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Donna L. Farber · 2013 to 2026
$31.3M
XENOGENEIC STEM CELL AND THYMIC REPLACEMENT IN AIDSP01AI039755 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SYKES, MEGAN · 1996 to 2004
$4.4M
Mechanisms of tolerance in recipients of combined kidney and bone marrow transplaR01AI084074 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SYKES, MEGAN · 2009 to 2010
$862k
Becton Dickinson LSR II Analytical Flow CytometerS10RR027050 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CLYNES, RAPHAEL A. · 2011 to 2011
$413k
IMMUNE TOLERANCE NETWORK-266015416-266015416N01AI015416 · NIAID · REGENTS OF THE UNIVERSITY OF C · PI BLUESTONE, JEFFREY A · 2002 to 2006
–
NCRR NIH HHS S10 RR027050NCRR NIH HHS S10RR027050NIAID NIH HHS N01 AI015416NIAID NIH HHS P01 AI039755NIAID NIH HHS P01 AI106697NIAID NIH HHS P01AI106697NIAID NIH HHS R01 AI084074NIAID NIH HHS R0I AI084074
6 · The paper itself

Abstract

T cell responses to allogeneic major histocompatibility complex antigens present a formidable barrier to organ transplantation, necessitating long-term immunosuppression to minimize rejection. Chronic rejection and drug-induced morbidities are major limitations that could be overcome by allograft tolerance induction. Tolerance was first intentionally induced in humans via combined kidney and bone marrow transplantation (CKBMT), but the mechanisms of tolerance in these patients are incompletely understood. We now establish an assay to identify donor-reactive T cells and test the role of deletion in tolerance after CKBMT. Using high-throughput sequencing of the T cell receptor B chain CDR3 region, we define a fingerprint of the donor-reactive T cell repertoire before transplantation and track those clones after transplant. We observed posttransplant reductions in donor-reactive T cell clones in three tolerant CKBMT patients; such reductions were not observed in a fourth, nontolerant, CKBMT patient or in two conventional kidney transplant recipients on standard immunosuppressive regimens. T cell repertoire turnover due to lymphocyte-depleting conditioning only partially accounted for the observed reductions in tolerant patients; in fact, conventional transplant recipients showed expansion of circulating donor-reactive clones, despite extensive repertoire turnover. Moreover, loss of donor-reactive T cell clones more closely associated with tolerance induction than in vitro functional assays. Our analysis supports clonal deletion as a mechanism of allograft tolerance in CKBMT patients. The results validate the contribution of donor-reactive T cell clones identified before transplant by our method, supporting further exploration as a potential biomarker of transplant outcomes.

Indexed as

Clonal DeletionKidney TransplantationTransplantation ToleranceAllograftsBone Marrow TransplantationComplementarity Determining RegionsGraft RejectionHumansImmunosuppression TherapyImmunosuppressive AgentsKidney Failure, ChronicLymphocyte Culture Test, MixedMajor Histocompatibility ComplexReceptors, Antigen, T-CellT-LymphocytesTreatment OutcomeComplementarity Determining RegionsImmunosuppressive AgentsReceptors, Antigen, T-Cell

Identifiers

PMID25632034
PMCPMC4360892
OpenAlexW2091936488

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.